<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="795">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150808</url>
  </required_header>
  <id_info>
    <org_study_id>Ph3 Vectron Tz</org_study_id>
    <secondary_id>ITDCZI93</secondary_id>
    <nct_id>NCT05150808</nct_id>
  </id_info>
  <brief_title>Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania</brief_title>
  <official_title>WHO Phase III Evaluation of Vectron T500 (Broflanilide 50WP) for IRS in Tanzania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Medical Research, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kilimanjaro Christian Medical Centre, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malaria is a major public health problem in Africa. An important way to control the disease&#xD;
      is by Indoor Residual Spraying of insecticide in houses. Insecticide resistance has become a&#xD;
      major problem. This trial will evaluate a novel insecticide against those insecticide&#xD;
      resistant mosquito vectors in Tanzania E Africa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Indoor residual spraying (IRS) is one of the major methods of malaria vector&#xD;
      control across sub-Saharan Africa, responsible for reducing malaria incidence by 10% since&#xD;
      2000. However, effective vector control is increasingly threatened by the rapid spread of&#xD;
      insecticide resistance. Consequently, there have been investments in the development of new&#xD;
      insecticides for IRS that possess novel modes of action with long residual activity, low&#xD;
      mammalian and environmental toxicity and minimal cross-resistance. VECTRONTM T500, a new IRS&#xD;
      insecticide containing the active ingredient broflanilide 50% WP, has been shown to be&#xD;
      efficacious against both pyrethroid-susceptible and -resistant vector strains on mud and&#xD;
      concrete substrates in phase II experimental hut trials in Tanzania.&#xD;
&#xD;
      Method: A two-arm non-inferiority cluster randomized controlled trial will be conducted in&#xD;
      Muheza District, Tanga Region, Tanzania. VECTRONTM T500 will be compared to the IRS&#xD;
      formulation Fludora® Fusion (active ingredients: clothianidin 50% WP + deltamethrin 6.25%&#xD;
      WP). The predominant malaria vectors in the study area are pyrethroid-resistant Anopheles&#xD;
      gambiae s.s., An. arabiensis and An. funestus s.s. Sixteen selected clusters of 75-200&#xD;
      households in each cluster will be pair-matched on baseline vector densities and allocated to&#xD;
      reference and intervention arms. Consenting households in the intervention arm will be&#xD;
      sprayed with VECTRONTM T500 and those in the reference arm will receive Fludora® Fusion.&#xD;
      Monthly CDC light traps will collect mosquitoes to determine vector density, indoor biting,&#xD;
      sporozoite and entomological inoculation rates (EIR). Phenotypic resistance to IRS active&#xD;
      ingredients will be assessed using CDC bottle bioassays. Molecular and metabolic resistance&#xD;
      mechanisms will be characterised among Anopheles field populations from both trial arms.&#xD;
      Residual efficacy of both brands of insecticide will be monitored for 12 months&#xD;
      post-spraying. A semi-structured questionnaire and focus group discussions will explore&#xD;
      social and cultural factors that influence acceptability, perceived adverse effects and&#xD;
      benefits of IRS.&#xD;
&#xD;
      Discussion: This protocol describes a phase III non-inferiority evaluation of a novel IRS&#xD;
      product to reduce the density and EIR of pyrethroid-resistant Anopheles vectors. If VECTRONTM&#xD;
      T500 proves non-inferior to Fludora® Fusion, it may be considered as an additional vector&#xD;
      control product for malaria prevention and insecticide resistance management schemes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cluster Randomised Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vector density</measure>
    <time_frame>12-15 months</time_frame>
    <description>Reduction in vector population density</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sporozoite rate</measure>
    <time_frame>12-15 months</time_frame>
    <description>Reduction in sporozoite rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Entomological inoculation rate EIR</measure>
    <time_frame>12-15 months</time_frame>
    <description>Reduction in EIR</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12500</enrollment>
  <condition>Malaria,Falciparum</condition>
  <arm_group>
    <arm_group_label>Intervention IRS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention IRS insecticide will be sprayed on the walls and ceilings of 8 clusters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control IRS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WHO approved IRS insecticide will be sprayed on the walls and ceilings of 8 clusters</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IRS insecticide: Vectron T500</intervention_name>
    <description>public health insecticide</description>
    <arm_group_label>Control IRS</arm_group_label>
    <arm_group_label>Intervention IRS</arm_group_label>
    <other_name>broflanilide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All households who consent to IRS malaria control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Medical Research</name>
      <address>
        <city>Muheza</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Tungu, Dr</last_name>
      <phone>+255715487232</phone>
      <email>patrickkjiatungu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>London School of Hygiene &amp; Tropical Medicine</name>
      <address>
        <city>London</city>
        <zip>WC1E 7HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark W Rowland, PhD</last_name>
      <phone>+44 7595090405</phone>
      <phone_ext>4719</phone_ext>
      <email>mark.rowland@lshtm.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Terri O O'Halloran, BA</last_name>
      <phone>+44 7762477027</phone>
      <phone_ext>4718</phone_ext>
      <email>Terri.O'Halloran@lshtm.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Tanzania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vector control</keyword>
  <keyword>insecticide</keyword>
  <keyword>indoor residual spraying of mosquitoes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

